The most common AE was gastrointestinal disorder (diarrhea or dyspepsia), and all other AEs were confirmed to be fully resolved after the trial, except for one minor increase in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) that failed to follow-up. The gene discussed is GPT; the disease is dyspepsia.